[membership level=”0,4″][The content continues for paid members only.] Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership] In late April, the U.S. House Energy and Commerce Committee released an updated “discussion draft” of the “21st Century Cures Act” – a piece of legislation that has been under development for over a year. It is intended to speed up the approval process for medicines that treat conditions currently lacking cures, and contains numerous other provisions in its 199 pages. Title 2 on development includes sections on precision medicine and on antibiotic drug development. The current bill does not focus specifically on CMC issues.